8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported: August 13, 2014)

PDI, INC.

(Exact name of Registrant as specified in its charter)

DELAWARE	0-24249	22-2919486
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Morris Corporate Center 1, Building A

300 Interpace Parkway,

Parsippany, NJ 07054

(Address of principal executive offices and zip Code)

(862) 207-7800

Registrant's telephone number, including area code:

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

The Board of Directors (the "Board") of PDI, Inc. (the "Company") expanded the size of the Company's Board from six to seven directors and appointed Heiner Dreismann, Ph.D. to fill the newly created Board vacancy as a Class I Director, effective August 13, 2014.

In connection with Dr. Dreismann's appointment to the Board, on August 13, 2014 he was granted approximately $60,000 in restricted stock units which vest ratably over a three year period.

A copy of the press release issued by the Company regarding Dr. Dreismann's appointment is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(c)	Exhibits
Exhibit No.	Description
99.1	Press Release dated August 13, 2014

* * * * * * *

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDI, INC.

By: /s/ Jeffrey Smith

Jeffrey Smith

Chief Financial Officer

Date: August 19, 2014

Exhibit Index

Exhibit No.	Description
99.1	Press Release dated August 13, 2014.

EX-99.1

Molecular Diagnostics Veteran Heiner Dreismann, Ph.D., Joins PDI, Inc. Board of Directors

Parsippany, NJ, AUGUST 13, 2014 - PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, today announced that Heiner Dreismann, Ph.D., former president and chief executive officer of Roche Molecular Systems, Inc., has joined its board of directors. Effective immediately, his addition brings the total number of board members to seven.

Dr. Dreismann possesses more than 27 years of global diagnostics experience in various positions at Roche Diagnostics and later Roche Molecular Systems (RMS), a business unit of Roche Diagnostics. In his last role at RMS, Dreismann oversaw the doubling of the molecular in vitro diagnostics business to over $1 billion and had overall responsibilities for business, corporate and R&D functions, as well as the respective staff.

“Dr. Dreismann has been on the cutting edge of the molecular diagnostics industry for his entire career, and his experience will be invaluable as a member of PDI’s board of directors,” said Jerry Belle, Chairman of the Board, PDI, Inc. "Dr. Dreismann’s extensive industry and technical knowledge, business acumen and ability to effect change perfectly aligns with our long term vision and strategy for PDI.”

Dr. Dreismann also serves on the boards of directors of several other public and privately held companies, including GeneNews, Stratos Genomics, Magellan Diagnostics, Singulex, Celula, Inc. and Myriad Genetics, among others.

“I am honored at this election to PDI’s board and look forward to contributing my insight and perspectives as a member,” said Dreismann. “The company is truly evolving as an innovative healthcare company and as a commercially-oriented molecular diagnostics company. I eagerly anticipate playing a role in helping to further its progress.”

Dr. Dreismann received his Ph.D. (summa cum laude) in Microbiology/Molecular Biology and Master’s degree in Biology from Westfaelische Wilhelms University, Muenster, and completed a Post-Doctoral Fellowship at the French Center for Nuclear Research in Saclay. He is a current member of the European Diagnostic Manufacturers Association, the American Society for Microbiology and New York Academy of Sciences.

About PDI, Inc.

PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. PDI’s Interpace Diagnostics subsidiary is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company’s Contract Sales business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. Its Group DCA division is a pioneer in insight-driven digital communication services and integrated multichannel message delivery.

For more information about PDI, Inc. or Interpace Diagnostics, please visit http://www.pdi-inc.com and www.interpacediagnostics.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and financial performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different from those expressed or implied by any forward-looking statement. For example, with respect to statements regarding projections of future revenues, growth and profitability, estimated gross profit and anticipated internal rate of return on investments actual results may differ materially from those set forth in this release based on the loss, early termination or significant reduction of any of our existing service contracts, the failure to meet performance goals in PDI's incentive-based arrangements with customers, the inability to secure additional business or our inability to develop more predictable, higher margin business through in-licensing or other means. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's previously filed Annual Report on Form 10-K for the year ended December 31, 2013 and current reports on Forms 10-Q and Forms 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:

Media:	Investors:
Caren Begun	Asher Dewhurst
Green Room Communications	Westwicke Partners
(856) 424-2023	(443) 213-0503
Caren@GreenRoomPR.com	Asher.Dewhurst@westwicke.com

# # #